Review

ev71 vp1 neutralizing antibody (Sino Biological)

Sino Biological is a verified supplier

Sino Biological manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Sino Biological ev71 vp1 neutralizing antibody
Ev71 Vp1 Neutralizing Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ev71 vp1 neutralizing antibody/product/Sino Biological
Average 92 stars, based on 4 article reviews

ev71 vp1 neutralizing antibody - by Bioz Stars, 2026-06

92/100 stars

Images

Image Search Results

Journal: PLoS ONE

Article Title: The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus

doi: 10.1371/journal.pone.0210553

Figure Lengend Snippet: Profile of Vero cell growth and EV71 amplification at different MOIs.

Article Snippet: The commercial Enterovirus 71 VP1 neutralizing antibody against EV71 genotype C4 (VP1/C4; 40013-H136, Sino biological Inc.) and VP2-specific MAB979/Anti-Enterovirus 71 antibody (MAB979; Merck Millipore) were treated with the same process to deplete the anti-VP1 and anti-VP2 antibodies.

Techniques: Amplification

$(A) Purification of EV71 antigens from different MOI cultures by sucrose density gradient ultracentrifugation (SDG) and identification of the viral particle-enriched fractions using SDS-PAGE analysis with silver staining. (a)-(d). EV71 cultures at different MOIs as indicated above. The lines labeled with FP and EP represent the distributed fractions of the infectious full particles and defective empty particles, respectively. The molecular weights of VP0, VP1, VP2, and VP3 are indicated. The molecular weight marker is shown on the right. (B) The ELISA yield, total protein, and specific activity of EV71 vaccines purified from different MOI cultures. After SDG purification, the EV71 particle-enriched fractions (fractions 6–13) were subsequently pooled and inactivated for productivity and quality evaluation. (C) Viral neutralization titers against the B4(E59) and C4(E36) subgenotypes elicited by EV71 vaccines from different MOI preparations. Significant differences between vaccine groups are indicated with the following symbols: *, p <0.05; **, p <0.01; and ***, p <0.001.$

Journal: PLoS ONE

Article Title: The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus

doi: 10.1371/journal.pone.0210553

Figure Lengend Snippet: (A) Purification of EV71 antigens from different MOI cultures by sucrose density gradient ultracentrifugation (SDG) and identification of the viral particle-enriched fractions using SDS-PAGE analysis with silver staining. (a)-(d). EV71 cultures at different MOIs as indicated above. The lines labeled with FP and EP represent the distributed fractions of the infectious full particles and defective empty particles, respectively. The molecular weights of VP0, VP1, VP2, and VP3 are indicated. The molecular weight marker is shown on the right. (B) The ELISA yield, total protein, and specific activity of EV71 vaccines purified from different MOI cultures. After SDG purification, the EV71 particle-enriched fractions (fractions 6–13) were subsequently pooled and inactivated for productivity and quality evaluation. (C) Viral neutralization titers against the B4(E59) and C4(E36) subgenotypes elicited by EV71 vaccines from different MOI preparations. Significant differences between vaccine groups are indicated with the following symbols: *, p <0.05; **, p <0.01; and ***, p <0.001.

Techniques: Purification, SDS Page, Silver Staining, Labeling, Molecular Weight, Marker, Enzyme-linked Immunosorbent Assay, Activity Assay, Neutralization

(A) Pooled viral particles from the vaccines prepared from (a) MOI 10 −1 , (b) MOI 10 −2 , (c) MOI 10 −4 , and (d) MOI 10 −6 cultures were observed by TEM. The morphologies of the FPs and EPs are indicated by arrows. The total numbers of viral particles in the different MOI samples were statistically counted, and the average sums of the FPs (B) and EPs (C) per field were plotted. (D) Percent normalization of FP and EP content to the total particles from each EV71 vaccine prepared from cultures with different MOIs. The total particle number for each EV71 vaccine produced using different MOIs was set as 100%. Significant differences between groups are indicated with the following symbols: *, p <0.05; **, p <0.01; and ***, p <0.001. ns: no significant difference was present between the groups.

Journal: PLoS ONE

Article Title: The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus

doi: 10.1371/journal.pone.0210553

Figure Lengend Snippet: (A) Pooled viral particles from the vaccines prepared from (a) MOI 10 −1 , (b) MOI 10 −2 , (c) MOI 10 −4 , and (d) MOI 10 −6 cultures were observed by TEM. The morphologies of the FPs and EPs are indicated by arrows. The total numbers of viral particles in the different MOI samples were statistically counted, and the average sums of the FPs (B) and EPs (C) per field were plotted. (D) Percent normalization of FP and EP content to the total particles from each EV71 vaccine prepared from cultures with different MOIs. The total particle number for each EV71 vaccine produced using different MOIs was set as 100%. Significant differences between groups are indicated with the following symbols: *, p <0.05; **, p <0.01; and ***, p <0.001. ns: no significant difference was present between the groups.

Techniques: Produced

Quality confirmation of purified FPs and EPs based on TEM observations (A) and SDS-PAGE analysis with silver staining (B). The molecular weights of VP0, VP1, VP2, and VP3 are indicated. (C) Measurement of neutralizing efficacy against the B4(E59) or C4(E36) subgenotype EV71 provided by anti-FP and anti-EP. The neutralizing titers raised from FPs were set as 100% normalized neutralization. The percent reduction in neutralization conferred by anti-EP was calculated. Evaluation of antigenic competition between EV71 vaccines composed of different FP and EP ratios. The neutralizing titer raised from 1 μg of FP was set as 100% normalized neutralization. The B4(E59) (D) or C4(E36) (E) neutralization conferred by antisera from manually prepared vaccines was calculated. Significant differences between groups are indicated by the following symbols: *, p <0.05; **, p <0.01; and ***, p <0.001.

Journal: PLoS ONE

Article Title: The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus

doi: 10.1371/journal.pone.0210553

Figure Lengend Snippet: Quality confirmation of purified FPs and EPs based on TEM observations (A) and SDS-PAGE analysis with silver staining (B). The molecular weights of VP0, VP1, VP2, and VP3 are indicated. (C) Measurement of neutralizing efficacy against the B4(E59) or C4(E36) subgenotype EV71 provided by anti-FP and anti-EP. The neutralizing titers raised from FPs were set as 100% normalized neutralization. The percent reduction in neutralization conferred by anti-EP was calculated. Evaluation of antigenic competition between EV71 vaccines composed of different FP and EP ratios. The neutralizing titer raised from 1 μg of FP was set as 100% normalized neutralization. The B4(E59) (D) or C4(E36) (E) neutralization conferred by antisera from manually prepared vaccines was calculated. Significant differences between groups are indicated by the following symbols: *, p <0.05; **, p <0.01; and ***, p <0.001.

Techniques: Purification, SDS Page, Silver Staining, Neutralization

(A) The binding specificities of anti-FP and anti-EP to the target virus B4(E59) were examined by adding virus antigens from B4(E59) or C4(E36) as competitors in a competition ELISA. The binding efficiencies of anti-FP (B) and anti-EP (C) to FP or EP from the B4(E59) virus were evaluated by competitive ELISA assay. The antisera, competitors, and binding targets are indicated. Inhibition of viral neutralization by anti-FP or anti-EP against the B4(E59) (D) or C4(E36) (E) virus was examined by FP- or EP-adsorption experiments. BSA was used as the non-EV71 competitor/antigen, as a negative control in the competitive ELISAs and viral neutralization inhibition assays. The substantial neutralizing titers (≥1:128) conferred by BSA-pre-adsorbed anti-FP or anti-EP against the viruses were set as 100% normalized neutralization. The increase in the neutralization inhibition percentage was measured by pretreating anti-FP and anti-EP with FP or EP adsorption. Significant differences between groups are indicated by the following symbols: *, p <0.05; **, p <0.01; and ***, p <0.001. ns: no significant difference was present between the groups.

Journal: PLoS ONE

Article Title: The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus

doi: 10.1371/journal.pone.0210553

Figure Lengend Snippet: (A) The binding specificities of anti-FP and anti-EP to the target virus B4(E59) were examined by adding virus antigens from B4(E59) or C4(E36) as competitors in a competition ELISA. The binding efficiencies of anti-FP (B) and anti-EP (C) to FP or EP from the B4(E59) virus were evaluated by competitive ELISA assay. The antisera, competitors, and binding targets are indicated. Inhibition of viral neutralization by anti-FP or anti-EP against the B4(E59) (D) or C4(E36) (E) virus was examined by FP- or EP-adsorption experiments. BSA was used as the non-EV71 competitor/antigen, as a negative control in the competitive ELISAs and viral neutralization inhibition assays. The substantial neutralizing titers (≥1:128) conferred by BSA-pre-adsorbed anti-FP or anti-EP against the viruses were set as 100% normalized neutralization. The increase in the neutralization inhibition percentage was measured by pretreating anti-FP and anti-EP with FP or EP adsorption. Significant differences between groups are indicated by the following symbols: *, p <0.05; **, p <0.01; and ***, p <0.001. ns: no significant difference was present between the groups.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Competitive ELISA, Inhibition, Neutralization, Adsorption, Negative Control

(A) The purity of maltose-binding protein (MBP) fusions with the VP0, VP1, VP2, and VP3 EV71 capsid proteins was confirmed by SDS-PAGE analysis with Coomassie blue staining. (B) The neutralization activities of protein-preabsorbed antisera or antibodies against the B4(E59) or C4(E36) virus were measured. The tested antisera are labeled. MAB979 is a monoclonal VP2-specific antibody that neutralizes the B4(E59) virus and was used as a positive control for MBP-VP2 adsorption. The anti-VP1/C4 monoclonal antibody confers neutralization activity against C4(E36) and was used as a positive control for MBP-VP1 adsorption. (C) Measurement of EV71 subgenotype neutralization inhibition by preabsorbed anti-FP. The neutralizing titer provided by anti-FP pre-adsorbed with MBP against individual viruses was set as 100% normalized neutralization. The increase in the percentage of neutralization inhibition conferred by anti-FP pre-adsorbed with MBP-VP1 or MBP-VP2 was calculated and normalized to the MBP-adsorption groups. The EV71 virus strains used for this experiment are labeled. Significant differences between groups are indicated by the following symbols: *, p <0.05; **, p <0.01; and ***, p <0.001. ns: no significant difference was present between the groups.

Journal: PLoS ONE

Article Title: The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus

doi: 10.1371/journal.pone.0210553

Figure Lengend Snippet: (A) The purity of maltose-binding protein (MBP) fusions with the VP0, VP1, VP2, and VP3 EV71 capsid proteins was confirmed by SDS-PAGE analysis with Coomassie blue staining. (B) The neutralization activities of protein-preabsorbed antisera or antibodies against the B4(E59) or C4(E36) virus were measured. The tested antisera are labeled. MAB979 is a monoclonal VP2-specific antibody that neutralizes the B4(E59) virus and was used as a positive control for MBP-VP2 adsorption. The anti-VP1/C4 monoclonal antibody confers neutralization activity against C4(E36) and was used as a positive control for MBP-VP1 adsorption. (C) Measurement of EV71 subgenotype neutralization inhibition by preabsorbed anti-FP. The neutralizing titer provided by anti-FP pre-adsorbed with MBP against individual viruses was set as 100% normalized neutralization. The increase in the percentage of neutralization inhibition conferred by anti-FP pre-adsorbed with MBP-VP1 or MBP-VP2 was calculated and normalized to the MBP-adsorption groups. The EV71 virus strains used for this experiment are labeled. Significant differences between groups are indicated by the following symbols: *, p <0.05; **, p <0.01; and ***, p <0.001. ns: no significant difference was present between the groups.

Techniques: Binding Assay, SDS Page, Staining, Neutralization, Labeling, Positive Control, Adsorption, Activity Assay, Inhibition

Review

Structured Review

Images

Similar Products

Image Search Results